2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1904

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards
Abstract Number: 1905

Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Abstract Number: 1906

Tofacitinib with and without Methotrexate Versus Adalimumab with Methotrexate for the Treatment of Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3b/4 Randomized Trial
Abstract Number: 1907

Safety, Pharmacokinetics, and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study on Rheumatoid Arthritis: 52-Week Results
Abstract Number: 1908

Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
Abstract Number: 1909

Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study
Abstract Number: 1910

ERAP1 Deficiency Implicates Long Peptides in Protection from HLA-B27-Induced Experimental Spondyloarthritis
Abstract Number: 1911

Impaired Control of Autoreactive T Cell Expansion Is Coupled with Type-1 Regulatory T Cell Deficiency in BALB/c ZAP70W163C Mutant Mice
Abstract Number: 1912

Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement
Abstract Number: 1913

Inter-Omic Analysis Reveals Functional Relationship between Diverse Gut Microbiota and Dysregulated Host Immune Response in HLA-B27-Mediated Experimental Spondyloarthritis
Abstract Number: 1914

Discovery of a Novel CD8+ T Cell Population in Ankylosing Spondylitis Implicates Gut-Joint Trafficking in the Disease
Abstract Number: 1915

Gut-Derived TNF As Risk Factor for the Development of Sacroiliac Inflammation
Abstract Number: 1916

The Interferon Gamma Release Assay Is a Novel Predictor of Disease Activity in Systemic Lupus Erythematosus
Abstract Number: 1917

A Novel Type I Interferon Biomarker on B Cell Predicts with Disease Activity in SLE and Can be Measured By Cell Surface Tetherin (CD317)
Abstract Number: 1918

Blood Levels of Complement Split Product iC3b and C3 Outperform Traditional Biochemical Measures of SLE Disease Activity in Associating with Active and Clinically Meaningful Changes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].